Antibe Provides Scientific Report on Its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346

Antibe Therapeutics (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has prepared a comprehensive report of the recently-completed Phase 2B study for its lead drug, ATB-346.

As quoted in the press release:

The study was completed in March 2018 and demonstrated unequivocal superiority in gastrointestinal safety compared to naproxen, the most prescribed NSAID in the United States.

The report provides a discussion of the study objectives and design, an analysis of the primary and secondary outcomes and additional effectiveness and safety parameters, and a brief discussion of the possible mechanisms related to the metabolism of ATB-346 responsible for the favourable pharmacokinetics and enhanced cyclo-oxygenase (COX) inhibition. The review article is available for download on Antibe’s website at: https://www.antibethera.com/news-media/scientific-publications/.

Click here to read the full press release.